


# Medicare Gives Clinical AI a Billing Identity Before It Has a Price Theory: The CY 2027 OPPS SaMS Proposal, the New O1 Status Indicator, the New Technology Bridge, and the Lab-Analysis Migration

JUL 22, 2026 • PAID



 **Podcast episode for paid subscriber only. Also available on Spotify.**



Thoughts on Healthcare Markets & Technology

 **Medicare Gives Clinical AI a Billing Identity Before It Has a Price Theory: The CY 2027 OPPS SaMS Proposal, the New O1 Status Indicator, the New Technology Bridge, and the Lab-Analysis**

Medicare just gave clinical AI a billing identity. It has not given it a price theory. That gap is the whole story in the 2027 OPPS proposed rule...

 Listen now

6 minutes ago • Thoughts on Healthcare

*To listen to paid episodes in Apple or Spotify, link your Substack subscription via the settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).*

Thoughts on Healthcare Markets &  
Technology is a reader-supported  
publication. To receive new posts and  
support my work, consider becoming a  
free or paid subscriber.

## Abstract

- The CY 2027 OPPS proposed rule, CMS-1850-P, does not create a universal payment category for clinical AI and does not price algorithmic value from first principles. Comments are due August 31, 2026.
- What it does: proposes an outpatient taxonomy for certain algorithmic clinical services, a new status indicator (O1) that makes many of them separately payable and a temporary New Technology APC band to hold rates roughly steady while CMS keeps arguing with itself about cost, evidence, packaging, and overuse.
- The vocabulary tell: CMS renames Software as a Service (a cloud business model) to Software as a Medical Service, or SaMS. Cute, and telling.
- Not all of it gets paid separately. Across source-defined groups totaling 36 HCPCS codes designated as SaMS in Table 61, a subset would carry O1 while others retain their existing status indicators (such as Q1, E1, N, or M) and packaging rules. Do not read this as “all the AI codes now get paid.”
- The rates are stability, not valuation. AI-QCT stays at 950.50 dollars even though a handful of early claims implied placement in the lowest New Technology APC payment band. Optellum keeps its assignment even though claims implied a 10 percent cut. This is legibility, not a value model.
- The sleeper is the lab move: CMS proposes to treat repeated algorithmic analysis of stored test data as an “other diagnostic test,” pulling it off the Clinical Laboratory Fee Schedule.
- This did not start in 2026. HeartFlow got separate OPPS payment back in 2019. MedPAC has been warning about bundle erosion and overuse the whole time.

# Table of Contents

1. CMS gives clinical AI a billing identity before it has a price theory
2. What SaMS actually is, and the quiet burial of SaaS
3. Why OPPS was never built to pay for software
4. Three cohorts, not one category, and O1 is a flag not a seal
5. The New Technology bridge, or rate stability wearing a pricing costume
6. The claims-data paradox: AI-QCT and Optellum
7. The lab migration is the real structural move
8. This started in 2018: HeartFlow and the lineage nobody remembers
9. MedPAC's counterweight and the value question CMS ducked
10. What O1 does not certify

## **CMS gives clinical AI a billing identity before it has a price theory**

The temptation with this proposal is to write the headline “Medicare starts paying for AI,” collect the clicks, and move on. Resist it, because it is wrong in both directions. Medicare has paid for algorithmic clinical software since 2018, so this is not a debut. And the CY 2027 OPPS rule does not actually price the value of AI, so this is not a valuation either. What it is, and this is the useful framing, is CMS handing of algorithmic clinical services a billing identity before it has figured out what they are worth. Legibility first, valuation later, maybe never.

That gap between “we can now see it in the claims” and “we know what to pay for it” is the entire story, and it is a genuinely hard problem rather than bureaucratic dithering. The stuff CMS is trying to pay for does not behave like the stuff OPPS was built to pay for. There is no gurney, no vial, no observable material resource to count. There is a subscription, a per-click license, and a proprietary model whose cost the vendor has every incentive not to disclose. So CMS is doing the only thing it can do at this stage, which is create a place to put these services on a claim, flag

of them as separately payable, and buy itself time with a temporary rate band wh keeps asking the questions it has been asking, unresolved, for years. Everything is a variation on that theme.



Continue reading this post for free, courtesy of Thoughts of  
Healthcare.

Claim my free post

Or purchase a paid subscription.

← Previous